drugset / Trial / NCT02910102

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102

Phase 2 Completed 38 enrolled Axovant Sciences Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.

Timeline

Start
2016-10
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject intepirdine Small molecule 35 mg Oral